The Effects of Botulinum Toxin Injection Treatment Administered to Patients with Adductor Spasmodic Dysphonia

Omori, Fukie; Ishige, Miyoko; Kobayashi, Takeo; Hirota, Eiko; Suzuki, Masuko

doi:10.5112/jjlp.58.237

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average period of effectiveness was 17.3 weeks. Recently, the group reported the longitudinal changes in the effectiveness after Botox injection [ 43 ] ( Figure 2 ). Commonly, subjective voice improvement was apparent within 1.8 ± 0.8 days, and it decreased as breathy hoarseness commenced on the following few days.…”

Section: Botulinum Toxin Therapymentioning

confidence: 99%

See 1 more Smart Citation

Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update

Hyodo

Hirose

Nagao

et al. 2022

Toxins

View full text Add to dashboard Cite

Spasmodic dysphonia (SD) is a rare neurological disorder that impairs phonatory function by triggering involuntary and intermittent contractions of the intrinsic laryngeal muscles. SD is classified into three types: adductor SD (AdSD), abductor SD (AbSD), and mixed SD. Of these, AdSD accounts for 90–95% of disease; younger females are predominantly affected. Botulinum toxin injection into the laryngeal muscles is safe, minimally invasive, and very effective. Here, we review the history of clinical research for SD conducted in Japan. The first use of botulinum toxin injection therapy to treat SD in Japan was by Kobayashi et al. in 1989. The group developed an objective mora (syllable) method to evaluate SD severity. Recently, we conducted a placebo-controlled, randomized, double-blinded clinical trial of botulinum toxin therapy for AdSD and an open-label trial for AbSD to obtain the approval of such therapy by the Japanese medical insurance system. The mora method revealed significant voice improvement and the evidence was of high quality. Additionally, a clinical trial of type 2 thyroplasty using titanium bridges confirmed the efficacy and safety of such therapy. These studies broadened the SD treatment options and have significantly benefited patients.

show abstract

Section: Botulinum Toxin Therapymentioning

confidence: 99%

“…(Reproduced with permission from Ref. [ 43 ] 2017, published by The Japan Society of Logopedics and Phoniatrics). Treatment effect is apparent on day 2, but it decreases as hoarseness commences.…”

Section: Figurementioning

confidence: 99%